PMID- 34046287
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210530
IS  - 2168-8184 (Print)
IS  - 2168-8184 (Electronic)
IS  - 2168-8184 (Linking)
VI  - 13
IP  - 5
DP  - 2021 May 22
TI  - Duloxetine for the Treatment of Chronic Low Back Pain: A Systematic Review of 
      Randomized Placebo-Controlled Trials.
PG  - e15169
LID - 10.7759/cureus.15169 [doi]
LID - e15169
AB  - This systematic review determines the efficacy and safety of duloxetine for 
      chronic low back pain (CLBP). We queried the PubMed, SCOPUS, and Ovid MEDLINE 
      databases. All level I and II randomized controlled studies published in the 
      English language investigating the efficacy of duloxetine for chronic low back 
      pain were included. Five studies (832 duloxetine-treated patients, 667 
      placebo-treated patients, and 41 duloxetine and placebo crossover analysis 
      patients) were analyzed. One study was level I evidence and four studies were 
      level II evidence. All five studies reported statistically significant 
      improvements in more than one back-pain-specific clinical outcome score with 
      duloxetine versus placebo. Four studies found that duloxetine 60 mg daily leads 
      to one or more statistically significant improvements versus placebo in Brief 
      Pain Inventory Severity (BPI-S) scores. All five studies found no significant 
      difference in serious adverse events (AEs) between the duloxetine and placebo 
      groups. One study found a higher rate of total AEs among the duloxetine 120 mg 
      group versus the placebo group; however, the same study did not find a 
      significant difference in total AEs among duloxetine 20 mg and 60 mg groups 
      versus placebo. Duloxetine is a safe and effective first-line option for the 
      treatment of CLBP. Current studies demonstrate that 60 mg taken once daily has 
      the highest efficacy for reducing pain and disability while minimizing minor 
      adverse effects. Further randomized controlled trials with long-term follow-up 
      are necessary to determine its long-term effects.
CI  - Copyright (c) 2021, Hirase et al.
FAU - Hirase, Takashi
AU  - Hirase T
AD  - Orthopedics and Sports Medicine, Houston Methodist Hospital, Houston, USA.
FAU - Hirase, Jessica
AU  - Hirase J
AD  - Psychiatry, Houston Methodist Hospital, Houston, USA.
FAU - Ling, Jeremiah
AU  - Ling J
AD  - Orthopedics and Sports Medicine, Houston Methodist Hospital, Houston, USA.
FAU - Kuo, Peggy H
AU  - Kuo PH
AD  - Orthopedics and Sports Medicine, Houston Methodist Hospital, Houston, USA.
FAU - Hernandez, Gilbert A
AU  - Hernandez GA
AD  - Orthopedics and Sports Medicine, Houston Methodist Hospital, Houston, USA.
FAU - Giwa, Kayode
AU  - Giwa K
AD  - Psychiatry, Houston Methodist Hospital, Houston, USA.
FAU - Marco, Rex
AU  - Marco R
AD  - Orthopedics and Sports Medicine, Houston Methodist Hospital, Houston, USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20210522
PL  - United States
TA  - Cureus
JT  - Cureus
JID - 101596737
PMC - PMC8140818
OTO - NOTNLM
OT  - chronic pain
OT  - duloxetine
OT  - low back pain
OT  - lumbar spondylosis
OT  - pain management
COIS- Takashi Hirase was supported by a Burroughs Wellcome Fund Physician-Scientist 
      Award to the Texas A&M University Academy of Physician Scientists.
EDAT- 2021/05/29 06:00
MHDA- 2021/05/29 06:01
PMCR- 2021/05/22
CRDT- 2021/05/28 07:27
PHST- 2021/05/28 07:27 [entrez]
PHST- 2021/05/29 06:00 [pubmed]
PHST- 2021/05/29 06:01 [medline]
PHST- 2021/05/22 00:00 [pmc-release]
AID - 10.7759/cureus.15169 [doi]
PST - epublish
SO  - Cureus. 2021 May 22;13(5):e15169. doi: 10.7759/cureus.15169.